About Tumor necrosis factor ligand superfamily member 11
Tumor necrosis factor ligand superfamily member 11 (TNFSF11) is a protein
from Homo sapiens identified by UniProt accession
O14788, 317 residues long.
MolForge cross-references it against 0 known binders and
879 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 11 |
| UniProt accession | O14788 |
| Gene | TNFSF11 |
| Organism | Homo sapiens |
| Length | 317 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (879)
Diseases linked to this target (Open Targets).
- osteoporosis · score 0.64
- Autosomal recessive malignant osteopetrosis · score 0.64
- autosomal recessive osteopetrosis 2 · score 0.60
- postmenopausal osteoporosis · score 0.59
- giant cell tumor · score 0.54
- alkaline phosphatase measurement · score 0.53
- breast cancer · score 0.51
- heel bone mineral density · score 0.51
- bone disease · score 0.50
- bone density · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14788-F1 | alphafold | PREDICTED | 79.19 | — |
Amino-acid sequence (317 residues)
MRRASRDYTK YLRGSEEMGG GPGAPHEGPL HAPPPPAPHQ PPAASRSMFV ALLGLGLGQV VCSVALFFYF RAQMDPNRIS EDGTHCIYRI LRLHENADFQ DTTLESQDTK LIPDSCRRIK QAFQGAVQKE LQHIVGSQHI RAEKAMVDGS WLDLAKRSKL EAQPFAHLTI NATDIPSGSH KVSLSSWYHD RGWAKISNMT FSNGKLIVNQ DGFYYLYANI CFRHHETSGD LATEYLQLMV YVTKTSIKIP SSHTLMKGGS TKYWSGNSEF HFYSINVGGF FKLRSGEEIS IEVSNPSLLD PDQDATYFGA FKVRDID
Explore Tumor necrosis factor ligand superfamily member 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets